Displaying 12 results:

HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy

Stefania Paolucci, Marta Premoli, Serena Ludovisi, Mario U Mondelli, Fausto Baldanti

Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring

Francesco R Simonetti, Dario Cattaneo, Nadia Zanchetta, Vania Giacomet, Valeria Micheli, Nadia Ciminera, Cristina Gervasoni

Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?

Julien Lupo, Ophélie Dos Santos, Raphaele Germi, Monique Baccard-Longère, Jean-Paul Stahl, Olivier Epaulard, Patrice Morand

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni

Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice

Maria A Skarnovich, Alexandra G Emelyanova, Nataliia V Petrova, Alena A Borshcheva, Evgeniy A Gorbunov, Oleg Yu Mazurkov, Maksim O Skarnovich, Sergey A Tarasov, Larisa N Shishkina, Oleg I Epstein

Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects

Martin O Behm, Ka L Yee, Li Fan, Paul Fackler

A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada

Anita C Benoit, Jaime Younger, Kerrigan Beaver, Randy Jackson, Mona Loutfy, Renée Masching, Tony Nobis, Earl Nowgesic, Doe O’Brien-Teengs, Wanda Whitebird, Art Zoccole, Mark Hull, Denise Jaworsky, Anita Rachlis, Sean Rourke, Ann N Burchell, Curtis Cooper, Robert Hogg, Marina B Klein, Nima Machouf, Julio Montaner, Chris Tsoukas, Janet Raboud, Building Bridges, the Canadian Observational Cohort Collaboration

Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects

Yutaka Saisho, Toru Ishibashi, Hidenori Fukuyama, Hiroyuki Fukase, Jingoro Shimada

Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials

Ana Arias, Antonio Aguilera, Vicente Soriano, Laura Benítez-Gutiérrez, Gemma Lledó, Daniel Navarro, Ana Treviño, Esteban Otero, José M Peña, Valentín Cuervas-Mons, Carmen de Mendoza

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin A Koteff, Brian Wynne, Judy Hopking, Catherine Granier, Michael Aboud